The responder in Group B2, who received gemcitabine, cisplatin, and S-1 with nivolumab, had microsatellite instability (MSI)-high tumors with a high tumor mutation burden (TMB) and germline MSH6 mutation. The gene discussed is MSH6; the disease is neoplasm.